Phosphatidylserine–beta-2-glycoprotein 1 complex

The **phosphatidylserine–beta-2-glycoprotein 1 complex** refers to the molecular association between **phosphatidylserine**, an anionic phospholipid expressed on the outer leaflet of apoptotic and activated cell membranes, and **beta-2-glycoprotein 1** (β2GPI, also known as apolipoprotein H), a plasma protein. β2GPI binds to phosphatidylserine on cell surfaces, forming a complex that is recognized as a major antigenic target of pathogenic autoantibodies in **antiphospholipid syndrome (APS)**, an autoimmune disorder marked by increased risk of thrombosis and pregnancy complications[1][2][3]. This complex modulates coagulation and complement pathways, participates in the clearance of apoptotic cells, and is involved in immune surveillance[2][3]. When autoantibodies bind the PS–β2GPI complex, they may disrupt normal anticoagulant functions and promote thrombosis and vascular inflammation[2][4][5]. The presence of anti-β2GPI antibodies is a key diagnostic biomarker for APS[2]. There are currently no small-molecule drugs that directly target this complex, but anticoagulants (e.g., warfarin, heparin) and immunomodulatory therapies are used to manage APS associated with these autoantibodies.

Other names

Phosphatidylserine–β2-glycoprotein I complexPS–β2GPI complexPhosphatidylserine–apolipoprotein H complexPS–ApoH complexAnionic phospholipid–β2GPI complex

Target of autoantibodies in antiphospholipid syndrome leading to pathological coagulation and thrombosis; Antibody-mediated interference with coagulation factor inhibition and regulation.